camrelizumab + paclitaxel + cisplatin + cyclophosphamide

This is a combination regimen consisting of four agents: - **Camrelizumab** is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. - **Paclitaxel** is a microtubule-stabilizing agent that inhibits cell division by promoting tubulin polymerization, leading to apoptosis in rapidly dividing cancer cells. - **Cisplatin** is a platinum-based chemotherapeutic that forms DNA crosslinks, disrupting DNA replication and transcription, ultimately inducing apoptosis. - **Cyclophosphamide** is an alkylating agent that interferes with DNA replication and transcription through the formation of covalent bonds with DNA. This combination brings together immunotherapy (camrelizumab) and cytotoxic chemotherapy (paclitaxel, cisplatin, cyclophosphamide) for synergistic anti-cancer effects. It has been investigated in various solid tumors including head and neck squamous cell carcinoma, ovarian cancer, and nasopharyngeal carcinoma[1][2][3][7][9]. The regimen aims to maximize tumor response rates by leveraging both direct cytotoxicity and immune-mediated mechanisms.